Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Efficacy and Safety of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2006-07-06
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 301
- Registration Number
- NCT00348712
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, York, United Kingdom
Safety and Efficacy of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2006-06-23
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 363
- Registration Number
- NCT00343980
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
Comparison of NovoFine® Needles (4 mm vs. 6 mm)
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-06-22
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 62
- Registration Number
- NCT00343343
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Århus C, Denmark
Efficacy Study of IL-21 to Treat Metastatic Melanoma
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-06-15
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 54
- Registration Number
- NCT00336986
- Locations
- 🇦🇺
Novo Nordisk Investigational Site, Westmead, Australia
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 576
- Registration Number
- NCT00333151
- Locations
- 🇨🇦
Novo Nordisk Investigational Site, Windsor, Canada
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-05-31
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 584
- Registration Number
- NCT00331851
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Watford, United Kingdom
Safety and Efficacy of Inhaled Insulin in Type 2 Diabetes
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2006-05-31
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 618
- Registration Number
- NCT00331604
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wirral, Merseyside, United Kingdom
Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma
Phase 3
Withdrawn
- Conditions
- First Posted Date
- 2006-05-09
- Last Posted Date
- 2012-06-27
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT00323570
- Locations
- 🇺🇸
Novo Nordisk Clinical Trial Call Center, Madison, Wisconsin, United States
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2006-05-05
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 596
- Registration Number
- NCT00322257
- Locations
- 🇨🇦
Novo Nordisk Investigational Site, Vancouver, Canada
Efficacy and Safety of Three Times a Day BIAsp-70 Compared to Two Times a Day BIAsp-30 in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 289
- Registration Number
- NCT00318786
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
© Copyright 2024. All Rights Reserved by MedPath